Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Investigational antibody demonstrates efficacy, safety for patients with...

Dr Thomas Martin, MD, University of California, San Francisco, USA

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study ( Dr Thomas Martin, MD, University of California, San Francisco, USA )

HIV-associated lymphoma responds well to stem cell transplantation

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

HIV-associated lymphoma responds well to stem cell transplantation ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )

Relapsed multiple myeloma responds to combination therapy with daratumumab

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

Relapsed multiple myeloma responds to combination therapy with daratumumab ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to...

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )

Stem cell transplantation safe for patients with HIV-associated lymphoma

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

Stem cell transplantation safe for patients with HIV-associated lymphoma ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )

Carfilzomib represents potent, effective addition to standard multiple myeloma...

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Post-transplant survival boosted by brentuximab vedotin in lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma...

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Children with aggressive leukaemia experiencing remission with T cell therapy

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

Children with aggressive leukaemia experiencing remission with T cell therapy ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Predicting the relapse of acute myeloid leukaemia with genetic screening

Dr Elaine Mardis - University of Washington, Washington, USA

Predicting the relapse of acute myeloid leukaemia with genetic screening ( Dr Elaine Mardis - University of Washington, Washington, USA )

New emerging treatments and challenges in MCL, MM and CLL: Expert panel...

Prof Simon Rule, Dr Maria-Victoria Mateos, Prof Paolo Ghia, Prof Antonio Palumbo

New emerging treatments and challenges in MCL, MM and CLL: Expert panel discussion ( Prof Simon Rule, Dr Maria-Victoria Mateos, Prof Paolo Ghia, Prof Antonio Palumbo )

More from ecancer